Drug Trial Radar · NCT06895499
Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.
Last checked: Nov 19, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Mar 19, 2025
Primary completion
Jan 30, 2026
Study completion Mar 30, 2026
Sponsor
- Lead sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Dermatology Hospital affiliated to Shandong First Medical University
- First posted
- Mar 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess efficacy safety and tolerability of HB0043 in adult patients with moderate to severe HS.
Conditions
- Hidradenitis Suppurativa
Interventions
HB0043Drug
Low dose
HB0043Drug
Medium dose
HB0043Drug
High dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability of HB0043 in Patients with Moderate to Severe HSTime frame: From randomization to end of study, assessed up to 24 weeks.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dermatology Hospital affiliated to Shandong First Medical University
Jinan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.